<DOC>
	<DOCNO>NCT00892112</DOCNO>
	<brief_summary>A prospective randomize double-blind placebo-controlled trail investigate effect high dos IVIg cardiac functional capacity virus presence subgroup patient chronic symptomatic ICM high PVB19 load heart .</brief_summary>
	<brief_title>Intravenous Immunoglobulin ( IVIg ) Parvovirus B19 ( PVB19 ) Mediated Cardiomyopathy</brief_title>
	<detailed_description>Rationale : Parvovirus B19 ( PVB19 ) persistence heart associate progressive cardiac dysfunction evolution idiopathic cardiomyopathy . Objective : A controlled trial investigate whether high dose intravenous immunoglobulin ( IVIg ) addition conventional heart failure therapy patient idiopathic cardiomyopathy PVB19 persistence heart achieve improvement cardiac function conjunction virus elimination . Study design : All patient undergo routine diagnostic work-up ( include physical examination , coronary angiogram , transthoracic echocardiogram , blood study endomyocardial biopsy ( EMB ) ) , treatment follow-up heart failure . Patients randomize either receive IVIg placebo top standard heart failure regimen .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Parvoviridae Infections</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Plasma Substitutes</mesh_term>
	<criteria>Idiopathic cardiomyopathy ( LVEF &lt; 45 % ) &gt; 6months Optimal conventional heart failure medication &gt; 3 month . PVB19 viral load &gt; 200 copies/mcg DNA endomyocardial biopsy ( EMBs ) . Signed informed consent Aged 18 75 year Other cause heart failure Significant coronary artery disease ( lesion &gt; 70 % stenosis ) Significant valvular disease Untreated hypertension ( blood pressure &gt; 140mmHg ) Substance abuse Chemotherapy induce Significant titer cardiotrophic virus ( EV , ADV , HHV6 , EBV ) Pregnancy lactation Systemic diseases sarcoidosis , giant cell myocarditis , hemochromatosis , systemic autoimmune disease . Treatment investigational drug within 7 day study entry previous enrolment study Known allergic reaction human plasma plasma product Having ongoing progressive terminal disease , include HIV infection Having renal insufficiency ( plasma creatinin &gt; 115Âµmol/L creatinin clearance &lt; 20 ml/min ) Having ongoing active disease cause general symptom e.g . chronic active hepatitis , persistent enterovirus infection ongoing systemic complaint Having detectable antiIgA antibody Active SLE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Cardiomyopathies</keyword>
	<keyword>Parvo B19 , Human</keyword>
</DOC>